pancreatic neuroendocrine tumor: Pancreatic endocrine tumor, also known as pancreatic neuroendocrine tumor (PNET), describes a group of endocrine tumors originating in the pancreas that are usually indolent and benign, but may have the potential to be malignant. They can be functional, exhibiting a hormonal hypersecretion syndrome, but can be non-functional presenting with non-specific symptoms and include insulinoma, glucagonoma, VIPoma, somatostatinoma (SSoma), PPoma and Zollinger-Ellison syndrome (ZES, or gastrinoma) and other ectopic hormone producing tumors (such as GRFoma) (see these terms).
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
178 |
4. Check minimum number of eventsNone |
178 |
5. Include endpointsNone |
178 |
6. Filter based on genotype QC (FinnGen only) |
173 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D13
Name in latin
Neoplasma benignum partis endocrinae pancreatis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Endocrine pancreas
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Endocrine pancreas
- Benign neoplasm of other and ill-defined parts of digestive system
- Benign neoplasm of other and ill-defined parts of digestive system
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 826 | 449 | 372 |
| Only index persons | 764 | 421 | 343 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.35 | 64.03 | 64.77 |
| Only index persons | 63.60 | 62.65 | 64.76 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 173 | 75 | 98 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.05 |
| Median age at first event (years) | 65.20 | 60.71 | 68.64 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_ENDOCRINE_PANCREAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_PANCREAS | 2.501 [1.71, 3.67] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.048 |
During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 343 females with CD2_BENIGN_ENDOCRINE_PANCREAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_PANCREAS | 2.53 [1.48, 4.32] | < 0.001 |
| Birth year | 0.985 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 73 out of 275 males with CD2_BENIGN_ENDOCRINE_PANCREAS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_ENDOCRINE_PANCREAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.26% | 0.423% |
| 5 | 1.356% | 2.896% |
| 10 | 3.129% | 6.819% |
| 15 | 6.062% | 13.219% |
| 20 | 10.476% | 20.537% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_ENDOCRINE_PANCREAS – Benign neoplasm: Endocrine pancreas
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data